Developing validated biomarkers (for diagnosis, such as using NOS2/iNOS to monitor the severity of the disease, such as with IL-18, and for treatment, like with IL-22 and IL-18) for identifying clinically significant immune pathways leading to AD is crucial for targeting specific mechanisms effectively. This evidence concerns the gene IL18 and Alzheimer disease.